Holen Sie sich die Stockscreener-App
5.15
5.50%
-0.30
Handel nachbörslich:
5.15
Schlusskurs vom Vortag:
$5.45
Offen:
$5.265
24-Stunden-Volumen:
40,913
Relative Volume:
0.85
Marktkapitalisierung:
$211.14M
Einnahmen:
$15.33M
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-2.9392
EPS:
-1.7522
Netto-Cashflow:
-
1W Leistung:
-1.53%
1M Leistung:
+3.00%
6M Leistung:
+2.79%
1J Leistung:
-3.38%
1-Tages-Spanne:
$5.11
$5.355
1-Wochen-Bereich:
$5.00
$5.63
52-Wochen-Spanne:
$3.50
$6.04
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Firmenname
Trisalus Life Sciences Inc
Sektor
Branche
Telefon
415 336 8917
Adresse
6272 WEST 91ST AVENUE, WESTMINSTER
Vergleichen Sie TLSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.15 | 211.14M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Lake Street | Buy |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Eingeleitet | ROTH MKM | Buy |
| 2024-10-25 | Eingeleitet | Northland Capital | Outperform |
| 2024-09-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-30 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 7.1% – Should You Sell? - Defense World
TriSalus shareholders elect directors, ratify auditor By Investing.com - Investing.com South Africa
TriSalus shareholders elect directors, ratify auditor - Investing.com
TriSalus Life Sciences Holds Annual Shareholder Meeting - TipRanks
Equities Analysts Set Expectations for TLSI FY2026 Earnings - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock By Investing.com - Investing.com Nigeria
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock - Investing.com
Bank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels - Nasdaq
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Bluefield Daily Telegraph
TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation - Stock Titan
Northern Trust Corp Has $161,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains TriSalus stock rating after CFO change By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains TriSalus stock rating after CFO change - Investing.com
TriSalus Life Sciences names new CFO - BizWest
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Comm - GuruFocus
TriSalus Life Sciences (TLSI) Names New Chief Financial Officer - GuruFocus
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Common Stock | TLSI Stock News - GuruFocus
TriSalus Life Sciences Appoints David Patience as CFO - marketscreener.com
TriSalus Life Sciences Appoints David Patience To Succeed James Young As CFO - Nasdaq
TriSalus Names David Patience Finance Chief as James Young Departs - MarketWatch
TriSalus Life Sciences appoints new CFO amid transition - Investing.com
TriSalus Life Sciences, Inc. Announces Chief Financial Officer Changes - marketscreener.com
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience - Business Wire
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 3.9% – Should You Buy? - Defense World
Roth Capital Issues Negative Estimate for TLSI Earnings - Defense World
TLSI FY2025 EPS Estimate Reduced by Cantor Fitzgerald - Defense World
TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market - MSN
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript - MSN
Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) PT at $10.93 - Defense World
Trisalus Life Sciences Q1 2025 Earnings Call Highlights - TipRanks
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: TriSalus Life Sciences projects 50% revenue growth in Q1 2025 - Investing.com Nigeria
TriSalus Life Sciences Reports Strong Q1 2025 Growth - TipRanks
Transcript : TriSalus Life Sciences, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
TriSalus (TLSI) Exceeds Revenue Expectations in Q1 | TLSI Stock News - GuruFocus
Trisalus Life Sciences Q1 Pretax Profit USD -10.37 Million - marketscreener.com
TriSalus Life Sciences, Inc. Updates Earnings Guidance for the Year 2025 - marketscreener.com
TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Wednesday - Defense World
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call - Business Wire
13,400 Shares in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Acquired by Renaissance Technologies LLC - Defense World
Geode Capital Management LLC Purchases 3,710 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Northland maintains TriSalus stock with $12.50 target - Investing.com Australia
Northland maintains TriSalus stock with $12.50 target By Investing.com - Investing.com India
TLSI Reports Strong Revenue Growth in First Quarter of 2025 | TL - GuruFocus
TriSalus Life Sciences (TLSI) Secures $22M Investment and Plans Capital Restructuring | TLSI Stock News - GuruFocus
TriSalus Life Sciences secures $22 million in funding By Investing.com - Investing.com India
TriSalus Life Sciences secures $22 million in funding - Investing.com
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results - Business Wire
Finanzdaten der Trisalus Life Sciences Inc-Aktie (TLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trisalus Life Sciences Inc-Aktie (TLSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Devlin Jodi | Chief of Clinical Operations |
May 19 '25 |
Sale |
5.18 |
4,764 |
24,678 |
52,764 |
| Marshak Richard | Chief Commercial Officer |
May 19 '25 |
Sale |
5.18 |
6,597 |
34,172 |
69,101 |
| Stevens Jennifer | Chief Regulatory Officer |
May 19 '25 |
Sale |
5.18 |
8,704 |
45,087 |
77,640 |
| Young James Emmett | Chief Financial Officer |
Feb 05 '25 |
Buy |
5.65 |
6,000 |
33,900 |
30,000 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 30 '25 |
Buy |
5.28 |
5,010 |
26,453 |
444,259 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 29 '25 |
Buy |
5.03 |
5,030 |
25,301 |
439,249 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 27 '25 |
Buy |
5.42 |
4,826 |
26,157 |
429,503 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 28 '25 |
Buy |
5.12 |
4,716 |
24,146 |
434,219 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 27 '25 |
Buy |
5.31 |
15,000 |
79,650 |
182,732 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 28 '25 |
Buy |
5.17 |
15,000 |
77,550 |
197,732 |
4.52%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):